ATE320186T1 - Nukleinsäure zur verwendung in gentherapie, welche therapie intestinale zell-expression der genen involviert - Google Patents
Nukleinsäure zur verwendung in gentherapie, welche therapie intestinale zell-expression der genen involviertInfo
- Publication number
- ATE320186T1 ATE320186T1 AT97942543T AT97942543T ATE320186T1 AT E320186 T1 ATE320186 T1 AT E320186T1 AT 97942543 T AT97942543 T AT 97942543T AT 97942543 T AT97942543 T AT 97942543T AT E320186 T1 ATE320186 T1 AT E320186T1
- Authority
- AT
- Austria
- Prior art keywords
- protein
- therapy
- administration
- genes
- intestinal cell
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title abstract 7
- 230000000968 intestinal effect Effects 0.000 title abstract 2
- 238000001415 gene therapy Methods 0.000 title 1
- 108020004707 nucleic acids Proteins 0.000 title 1
- 150000007523 nucleic acids Chemical class 0.000 title 1
- 102000039446 nucleic acids Human genes 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 abstract 4
- 230000001225 therapeutic effect Effects 0.000 abstract 3
- 230000036765 blood level Effects 0.000 abstract 1
- 230000010307 cell transformation Effects 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 abstract 1
- 230000007774 longterm Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Endocrinology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/717,084 US6225290B1 (en) | 1996-09-19 | 1996-09-19 | Systemic gene therapy by intestinal cell transformation |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE320186T1 true ATE320186T1 (de) | 2006-04-15 |
Family
ID=24880656
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT97942543T ATE320186T1 (de) | 1996-09-19 | 1997-09-18 | Nukleinsäure zur verwendung in gentherapie, welche therapie intestinale zell-expression der genen involviert |
Country Status (10)
Country | Link |
---|---|
US (4) | US6225290B1 (de) |
EP (1) | EP0939590B1 (de) |
JP (1) | JP2001502303A (de) |
AT (1) | ATE320186T1 (de) |
AU (1) | AU729457B2 (de) |
CA (1) | CA2264744A1 (de) |
DE (1) | DE69735496T2 (de) |
DK (1) | DK0939590T3 (de) |
ES (1) | ES2256896T3 (de) |
WO (1) | WO1998011779A1 (de) |
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7888466B2 (en) | 1996-01-11 | 2011-02-15 | Human Genome Sciences, Inc. | Human G-protein chemokine receptor HSATU68 |
US6225290B1 (en) * | 1996-09-19 | 2001-05-01 | The Regents Of The University Of California | Systemic gene therapy by intestinal cell transformation |
US20030129750A1 (en) * | 1998-02-05 | 2003-07-10 | Yitzhack Schwartz | Homing of donor cells to a target zone in tissue using active therapeutics or substances |
US7749215B1 (en) * | 1998-02-05 | 2010-07-06 | Biosense, Inc. | Intracardiac cell delivery and cell transplantation |
US20030113303A1 (en) * | 1998-02-05 | 2003-06-19 | Yitzhack Schwartz | Homing of embryonic stem cells to a target zone in tissue using active therapeutics or substances |
DE69943022D1 (de) | 1998-03-19 | 2011-01-20 | Human Genome Sciences Rockville | Der gemeinsamen gamma-kette ähnlicher zytokinrezeptor |
SK287538B6 (sk) | 1998-03-20 | 2011-01-04 | Commonwealth Scientific And Industrial Research Organisation | Syntetický gén obsahujúci dispergovanú alebo cudzorodú deoxyribonukleovú molekulu, génový konštrukt obsahujúci tento syntetický gén a prípravok obsahujúci tento syntetický gén |
AUPP249298A0 (en) * | 1998-03-20 | 1998-04-23 | Ag-Gene Australia Limited | Synthetic genes and genetic constructs comprising same I |
CN1297481A (zh) * | 1998-05-06 | 2001-05-30 | 法玛西雅厄普约翰美国公司 | 向非人脊椎动物导入编码非人脊椎动物肽激素或细胞因子的裸dna或rna |
JPH11335269A (ja) * | 1998-05-19 | 1999-12-07 | Hisamitsu Pharmaceut Co Inc | 遺伝子関連医薬の経口投与固形製剤 |
EP1889914A1 (de) * | 1999-02-19 | 2008-02-20 | Engene, Inc. | Zusammensetzungen für die Gentherapie von Diabetes |
EP1153131B1 (de) * | 1999-02-19 | 2007-09-26 | enGene, Inc. | Zusammensetzungen zur gentherapie von diabetes |
AU3501700A (en) | 1999-02-26 | 2000-09-14 | Human Genome Sciences, Inc. | Human endokine alpha and methods of use |
ATE452973T1 (de) * | 1999-03-04 | 2010-01-15 | Revivicor Inc | Genetische veränderung von somatischen zellen und deren verwendungen |
US6423885B1 (en) | 1999-08-13 | 2002-07-23 | Commonwealth Scientific And Industrial Research Organization (Csiro) | Methods for obtaining modified phenotypes in plant cells |
US6953658B2 (en) | 2000-03-09 | 2005-10-11 | Diadexus, Inc. | Method of diagnosing, monitoring, staging, imaging and treating gastrointestinal cancer |
NZ521199A (en) * | 2000-03-13 | 2004-11-26 | Engene Inc | Mucosal cells producing nutrient-regulated protein expressed by a transgene comprising an expression control element linked with a nucleic acid encoding protein, for treating diabetes |
KR20080023768A (ko) * | 2000-03-30 | 2008-03-14 | 화이트헤드 인스티튜트 포 바이오메디칼 리서치 | Rna 간섭의 rna 서열 특이적인 매개체 |
JP2003530838A (ja) | 2000-04-12 | 2003-10-21 | ヒューマン ゲノム サイエンシズ インコーポレイテッド | アルブミン融合タンパク質 |
GB0010630D0 (en) * | 2000-05-04 | 2000-06-21 | Univ Wales Medicine | Sequence |
EP1294949A4 (de) | 2000-06-15 | 2004-08-25 | Human Genome Sciences Inc | Menschlicher tumornekrosefaktor delta und epsilon |
US6774223B2 (en) | 2000-06-28 | 2004-08-10 | Diadexus, Inc. | Method of diagnosing, monitoring, staging, imaging and treating colon cancer |
CZ302719B6 (cs) * | 2000-12-01 | 2011-09-21 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Izolovaná molekula dvouretezcové RNA, zpusob její výroby a její použití |
US20020151068A1 (en) * | 2001-01-03 | 2002-10-17 | Board Of Regents, The University Of Texas System | Compositions and methods for the diagnosis and treatment of organophosphate toxicity |
EP1366058B1 (de) | 2001-02-09 | 2011-01-26 | Human Genome Sciences, Inc. | Humaner g-protein-chemokinrezeptor (ccr5) hdgnr10 |
WO2002080852A2 (en) * | 2001-04-04 | 2002-10-17 | Digital Gene Technologies, Inc. | Genes expressed in intestinal epithelium and peyer's patch m cells |
AU2002257142B2 (en) | 2001-04-13 | 2008-09-04 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 |
WO2002083080A2 (en) * | 2001-04-17 | 2002-10-24 | Genetix Pharmaceuticals, Inc. | Method of treating arthritis using lentiviral vectors in gene therapy |
KR20030022094A (ko) * | 2001-05-24 | 2003-03-15 | (주)휴먼디엔에이테크놀로지 | 모낭에 존재하는 새로운 제 2 케라티노사이트 성장인자유사체 |
US20050118719A1 (en) * | 2001-11-07 | 2005-06-02 | Schmidt Michael G. | Nucleic acid delivery and expression |
US20030135195A1 (en) * | 2002-01-16 | 2003-07-17 | Oscar Jimenez | Highly lubricious hydrophilic coating utilizing dendrimers |
WO2003068170A2 (en) | 2002-02-14 | 2003-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | Enzyme treatment of foodstuffs for celiac sprue |
EP1490520A4 (de) * | 2002-03-12 | 2006-06-07 | Surface Logix Inc | Testvorrichtung, die die absorption, den stoffwechsel, die permeabiltät und/oder toxizität einer kandidatenverbindung analysiert |
US7374930B2 (en) * | 2002-05-21 | 2008-05-20 | Expression Genetics, Inc. | GLP-1 gene delivery for the treatment of type 2 diabetes |
AU2003273206B2 (en) * | 2002-05-31 | 2009-08-20 | Children's Hospital Medical Center | Method, composition and kit for antigenic binding of Norwalk-Like viruses |
US7977098B2 (en) | 2002-05-31 | 2011-07-12 | Children's Hospital Medical Center | Antigenic binding patterns of norovirus to human histo-blood group antigens |
US20040016013A1 (en) * | 2002-07-18 | 2004-01-22 | Gonzalo Hortelano | Transgenic animals produced using oral administration of a genetic agent coupled to a transporting agent |
US20040014698A1 (en) * | 2002-07-18 | 2004-01-22 | Gonzalo Hortelano | Oral administration of therapeutic agent coupled to transporting agent |
US20040014704A1 (en) * | 2002-07-18 | 2004-01-22 | Gonzalo Hortelano | Oral administration of therapeutic agent coupled to transporting agent induces tolerance |
NZ539423A (en) * | 2002-10-24 | 2006-12-22 | Biogen Idec Inc | Ferritin heavy chain gene locus vectors that include 5' and 3' sequences, which can convey high levels of expression to heterologous genes in stable transfectants |
US20080026077A1 (en) * | 2002-11-12 | 2008-01-31 | John Hilfinger | Methods and compositions of gene delivery agents for systemic and local therapy |
US20050026859A1 (en) * | 2002-11-12 | 2005-02-03 | John Hilfinger | Methods and compositions of gene delivery agents for systemic and local therapy |
WO2005032574A1 (en) * | 2003-10-03 | 2005-04-14 | The Board Of Trustees Of The Leland Stanford Junior University | Modulation of gastrointestinal epithelium proliferation through the wnt signaling pathway |
US20050208032A1 (en) * | 2004-01-16 | 2005-09-22 | Gonzalo Hortelano | Oral administration of therapeutic agent coupled to transporting agent |
WO2007070948A1 (en) * | 2005-12-20 | 2007-06-28 | Arana Therapeutics Limited | Anti-inflammatory dab |
WO2008020318A2 (en) * | 2006-03-30 | 2008-02-21 | Engene, Inc. | Non-viral compositions and methods for transfecting gut cells in vivo |
CA2706600A1 (en) * | 2007-11-26 | 2009-06-04 | Plant Bioscience Limited | Novel polypeptides having endolysin activity and uses thereof |
CA2726193C (en) | 2008-06-03 | 2018-11-27 | University Of Rochester | Methods of treating inflammatory intestinal disease and managing symptoms thereof |
US20100068254A1 (en) * | 2008-09-16 | 2010-03-18 | Mahalaxmi Gita Bangera | Modifying a medicament availability state of a final dosage form |
US20100068233A1 (en) * | 2008-09-16 | 2010-03-18 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Modifiable dosage form |
US20100068235A1 (en) * | 2008-09-16 | 2010-03-18 | Searete LLC, a limited liability corporation of Deleware | Individualizable dosage form |
US20100068152A1 (en) * | 2008-09-16 | 2010-03-18 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Ex vivo modifiable particle or polymeric based final dosage form |
US20100069887A1 (en) * | 2008-09-16 | 2010-03-18 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Multiple chamber ex vivo adjustable-release final dosage form |
US20100068275A1 (en) * | 2008-09-16 | 2010-03-18 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Personalizable dosage form |
US20100068278A1 (en) * | 2008-09-16 | 2010-03-18 | Searete Llc, A Limited Liablity Corporation Of The State Of Delaware | Ex vivo modifiable medicament release-associations |
US20100068153A1 (en) * | 2008-09-16 | 2010-03-18 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Ex vivo activatable final dosage form |
US20100069821A1 (en) * | 2008-09-16 | 2010-03-18 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Ex vivo modifiable medicament release-sites final dosage form |
GB0908949D0 (en) | 2009-05-26 | 2009-07-01 | Plant Bioscience Ltd | Novel polypeptides having endolysin activity and uses thereof |
WO2010144602A2 (en) | 2009-06-09 | 2010-12-16 | Children's Hospital Medical Center | Antigen-norovirus p-domain monomers and dimers, antigen-norovirus p-particle molecules, and methods for their making and use |
US9321803B2 (en) | 2013-07-12 | 2016-04-26 | Children's Hospital Medical Center | Compositions and methods for inhibiting norovirus infection |
US10869898B2 (en) | 2014-04-01 | 2020-12-22 | Rubius Therapeutics, Inc. | Methods and compositions for immunomodulation |
US20160160229A1 (en) * | 2014-12-09 | 2016-06-09 | THC Farmaceuticals, Inc. | Methods of producing antibody-rich cannabis and honeysuckle plants |
WO2018182983A1 (en) | 2017-03-28 | 2018-10-04 | Children's Hospital Medical Center | Norovirus s particle based vaccines and methods of making and using same |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5643579A (en) * | 1984-11-01 | 1997-07-01 | American Home Products Corporation | Oral vaccines |
US6241982B1 (en) * | 1988-03-21 | 2001-06-05 | Chiron Corporation | Method for treating brain cancer with a conditionally lethal gene |
JPH04504950A (ja) | 1988-11-23 | 1992-09-03 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 位置特異的挿入ベクターおよびこれを用いた方法 |
DK0465529T3 (da) | 1989-03-21 | 1998-10-05 | Vical Inc | Ekspression af exogene polynukleotidsekvenser i et hvirveldyr |
US5328470A (en) * | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
WO1991006309A1 (en) | 1989-11-03 | 1991-05-16 | Vanderbilt University | Method of in vivo delivery of functioning foreign genes |
DE69233013T2 (de) | 1991-08-20 | 2004-03-04 | The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer | Adenovirus vermittelter gentransfer in den gastrointestinaltrakt |
WO1993019660A1 (en) | 1992-04-03 | 1993-10-14 | Baylor College Of Medicine | Gene therapy using the intestine |
WO1994016057A1 (en) * | 1992-12-31 | 1994-07-21 | Dana-Farber Cancer Institute, Inc. | Enhancer sequence for modulating expression in epithelial cells |
SG54115A1 (en) * | 1993-04-27 | 1998-11-16 | Gerber Scient Products Inc | Thermal printing apparatus with improved power supply |
JPH08511423A (ja) | 1993-06-10 | 1996-12-03 | ジェネティック セラピー,インコーポレイテッド | 血友病治療のためのアデノウイルスベクター |
US5681744A (en) * | 1995-03-17 | 1997-10-28 | Greenstein; Robert J. | Delivery and expression of heterologus genes using upstream enhancer regions of mammalian gene promoters |
US5885971A (en) * | 1995-03-24 | 1999-03-23 | The Regents Of The University Of California | Gene therapy by secretory gland expression |
AU6097896A (en) | 1995-06-07 | 1996-12-30 | Alza Corporation | Oral delivery of gene constructs |
US6143211A (en) * | 1995-07-21 | 2000-11-07 | Brown University Foundation | Process for preparing microparticles through phase inversion phenomena |
US6248720B1 (en) * | 1996-07-03 | 2001-06-19 | Brown University Research Foundation | Method for gene therapy using nucleic acid loaded polymeric microparticles |
US6225290B1 (en) * | 1996-09-19 | 2001-05-01 | The Regents Of The University Of California | Systemic gene therapy by intestinal cell transformation |
-
1996
- 1996-09-19 US US08/717,084 patent/US6225290B1/en not_active Expired - Lifetime
-
1997
- 1997-09-18 EP EP97942543A patent/EP0939590B1/de not_active Expired - Lifetime
- 1997-09-18 DK DK97942543T patent/DK0939590T3/da active
- 1997-09-18 AT AT97942543T patent/ATE320186T1/de not_active IP Right Cessation
- 1997-09-18 WO PCT/US1997/016523 patent/WO1998011779A1/en active IP Right Grant
- 1997-09-18 DE DE69735496T patent/DE69735496T2/de not_active Expired - Fee Related
- 1997-09-18 ES ES97942543T patent/ES2256896T3/es not_active Expired - Lifetime
- 1997-09-18 AU AU44221/97A patent/AU729457B2/en not_active Ceased
- 1997-09-18 US US09/254,988 patent/US6258789B1/en not_active Expired - Lifetime
- 1997-09-18 JP JP10514853A patent/JP2001502303A/ja not_active Ceased
- 1997-09-18 CA CA002264744A patent/CA2264744A1/en not_active Abandoned
-
2001
- 2001-03-16 US US09/811,323 patent/US6831070B2/en not_active Expired - Fee Related
-
2004
- 2004-08-03 US US10/911,082 patent/US20050026863A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US6258789B1 (en) | 2001-07-10 |
EP0939590A1 (de) | 1999-09-08 |
EP0939590B1 (de) | 2006-03-15 |
JP2001502303A (ja) | 2001-02-20 |
AU729457B2 (en) | 2001-02-01 |
WO1998011779A1 (en) | 1998-03-26 |
DE69735496T2 (de) | 2006-09-21 |
DE69735496D1 (de) | 2006-05-11 |
DK0939590T3 (da) | 2006-07-24 |
CA2264744A1 (en) | 1998-03-26 |
US6831070B2 (en) | 2004-12-14 |
ES2256896T3 (es) | 2006-07-16 |
AU4422197A (en) | 1998-04-14 |
US20020039574A1 (en) | 2002-04-04 |
EP0939590A4 (de) | 2002-09-04 |
US6225290B1 (en) | 2001-05-01 |
US20050026863A1 (en) | 2005-02-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE320186T1 (de) | Nukleinsäure zur verwendung in gentherapie, welche therapie intestinale zell-expression der genen involviert | |
US5821235A (en) | Gene therapy using the intestine | |
Martin et al. | Gene transfer to intact mesenteric arteries by electroporation | |
Amano et al. | Anatomy and histology of rodent and human major salivary glands—Overview of the japan salivary gland society-sponsored workshop— | |
Hsu et al. | Ontogeny of expression of transforming growth factor-β1 (TGF-β1), TGF-β3, and TGF-β receptors I and II in fetal rat fibroblasts and skin | |
AU666142B2 (en) | Viral recombinant vectors for expression in muscle cells | |
DE69435096T2 (de) | Zusammensetzung zur in vivo erzeugung von therapeutischen produkten | |
Yin et al. | Gene therapy for streptozotocin-induced diabetic mice by electroporational transfer of naked human insulin precursor DNA into skeletal muscle in vivo | |
Lesbordes et al. | In vivo electrotransfer of the cardiotrophin-1 gene into skeletal muscle slows down progression of motor neuron degeneration in pmn mice | |
JPH11502413A (ja) | 分泌腺発現による遺伝子治療 | |
JP3578761B2 (ja) | 表皮ケラチン細胞成長因子の治療目的での使用 | |
Li et al. | Gene therapy for psoriasis in the K14‐VEGF transgenic mouse model by topical transdermal delivery of interleukin‐4 using ultradeformable cationic liposome | |
JP2009526571A (ja) | 遺伝子発現の熱的制御または電磁気的制御のための方法および遺伝子発現の熱的制御または電磁気的制御のための装置 | |
EA005496B1 (ru) | Растворимый гетеродимерный рецептор цитокина | |
TWI308492B (de) | ||
HUP9800028A2 (hu) | Több tumor esetében rendellenes sejtszaporodás előidézésében közrejátszó gének | |
Islamov et al. | Epidural stimulation combined with triple gene therapy for spinal cord injury treatment | |
CN102462837A (zh) | 抗炎组合物 | |
Islamov et al. | New therapy for spinal cord injury: Autologous genetically-enriched leucoconcentrate integrated with epidural electrical stimulation | |
Tredget et al. | Regulation of collagen synthesis and messenger RNA levels in normal and hypertrophic scar fibroblasts in vitro by interferon alfa‐2b | |
JP2001515713A (ja) | 散在性の若しくはアクセス困難な細胞又は組織を有するヒト病状の処置又は診断方法 | |
HUP0002913A2 (hu) | Eljárások és készítmények szekretált fehérjéket, például béta-interferont kódoló géneket alkalmazó terápiára | |
Baum et al. | The mouth is a gateway to the body: gene therapy in 21st century dental practice | |
Culliton | Designing Cells to Deliver Drugs: As technical roadblocks slow some approaches to gene therapy, new avenues may lead to treatments for disorders including AIDS, cancer, heart disease, and emphysema | |
CN108685850A (zh) | 模块化组装的组合生物药物联合递送系统及应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 0939590 Country of ref document: EP |
|
REN | Ceased due to non-payment of the annual fee |